NASDAQ:RNTX Rein Therapeutics (RNTX) Stock Price, News & Analysis $1.39 +0.26 (+23.01%) As of 08/29/2025 04:00 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOwnershipSEC FilingsTrendsBuy This Stock About Rein Therapeutics Stock (NASDAQ:RNTX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Rein Therapeutics alerts:Sign Up Key Stats Today's Range$1.15▼$1.4050-Day Range$1.10▼$1.5552-Week Range$1.04▼$4.40Volume224,852 shsAverage Volume61,583 shsMarket Capitalization$32.40 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingHold Company Overview Rein Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of a novel class of therapeutics for the treatment of cancer and other diseases. It focuses on its lead product candidate, ALRN-6924, which is a cell-permeating peptide that disrupts the interaction of p53 suppressors MDM2 and MDMX with tumor suppressor p53 to reactivate tumor suppression in non-mutant, or wild-type, p53 cancers. The company was founded by Gregory L. Verdine, Rosana Kapeller, Huw M. Nash, Joseph A. Yanchik III, and Loren David Walensky on August 6, 2001 and is headquartered in Austin, TX. Read More Receive RNTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Rein Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. RNTX Stock News HeadlinesRein Therapeutics (NASDAQ:RNTX) Cut to "Hold" at Brookline Capital ManagementAugust 21, 2025 | americanbankingnews.comBrookline Capital Downgrades Rein Therapeutics (RNTX)August 19, 2025 | msn.comAmazon’s big Bitcoin embarrassmentBitcoin just passed Amazon in total market cap — but most investors are missing the bigger opportunity. While the crowd buys Bitcoin outright, trader Larry Benedict is using a method called “Bitcoin Skimming” to target 6x, 9x, even 22x bigger profits. He reveals how it works in a free video.August 30 at 2:00 AM | Brownstone Research (Ad)Rein announces U.K. MHRA authorized to initiate Phase 2 ‘RENEW’ trialAugust 19, 2025 | msn.comRein Therapeutics Wins U.K. Approval to Launch Phase 2 Clinical Trial of LTI-03 in Idiopathic Pulmonary FibrosisAugust 19, 2025 | globenewswire.comRein Therapeutics to Present Novel IPF Science and Clinical Development Insights at IPF Summit 2025August 14, 2025 | globenewswire.comXtalPi and DoveTree Announce Landmark $6 Billion AI Drug Discovery CollaborationAugust 7, 2025 | finance.yahoo.comRein Therapeutics Enters into Agreements for up to $21 Million in Flexible FinancingJuly 30, 2025 | finance.yahoo.comSee More Headlines RNTX Stock Analysis - Frequently Asked Questions How have RNTX shares performed this year? Rein Therapeutics' stock was trading at $2.05 at the start of the year. Since then, RNTX shares have decreased by 32.2% and is now trading at $1.39. How were Rein Therapeutics' earnings last quarter? Rein Therapeutics Inc. (NASDAQ:RNTX) posted its quarterly earnings results on Thursday, August, 14th. The company reported ($0.28) earnings per share for the quarter, missing analysts' consensus estimates of ($0.22) by $0.06. Who are Rein Therapeutics' major shareholders? Top institutional shareholders of Rein Therapeutics include BIOS Capital Management LP (7.34%), Voss Capital LP (6.22%), University of Texas Texas AM Investment Management Co. (2.31%) and Cable Car Capital LP (1.82%). How do I buy shares of Rein Therapeutics? Shares of RNTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings8/14/2025Today8/30/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:RNTX CIK1420565 WebN/A Phone(737) 802-1989FaxN/AEmployees9Year FoundedN/AProfitability EPS (Trailing Twelve Months)($2.69) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$62.88 million Net MarginsN/A Pretax MarginN/A Return on Equity-141.11% Return on Assets-33.83% Debt Debt-to-Equity RatioN/A Current Ratio0.86 Quick Ratio0.86 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash Flow$0.55 per share Price / Cash Flow2.52 Book Value$0.13 per share Price / Book10.69Miscellaneous Outstanding Shares23,310,000Free Float22,116,000Market Cap$32.40 million OptionableN/A Beta1.31 5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report This page (NASDAQ:RNTX) was last updated on 8/30/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredHow “Trump’s New Dollar” Could Impact Your WealthPresident Trump just signed a game-changing law… That could soon upgrade the U.S. dollar in your checking a...Brownstone Research | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredMy NEXT $1 Trillion PredictionJames Altucher is making his next trillion-dollar prediction — and this time, it’s not Apple. He believes Elon...Paradigm Press | SponsoredTrump’s national nightmare is hereAI is no longer just about chatbots — it’s becoming the backbone of the global economy. While U.S. firms push ...Porter & Company | Sponsored“Sell Nvidia before earnings”Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | SponsoredA New Way to Double Your Retirement Income?Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boo...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Rein Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Rein Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
